Sponsor study identifier
interventional
50
1 country
3
Study Start
May 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2014
Actual (reported)Study Completion
October 2014
Actual (reported)The objective of this study is to assess the effects of oral cannabidiol (CBD; 0, 200, 400, 800 mg) on smoked marijuana's (0, 5.6% THC) subjective, reinforcing, cognitive, and cardiovascular effects. This experiment is expected to reveal CBD's intrinsic effects when combined with placebo marijuana, as well as its ability to modulate the behavioral effects of active marijuana.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2014
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 29, 2013
Actual (reported)May 2013
Date type not reportedThis date has not been verified as actual or estimated.
May 1, 2013
Actual (reported)October 2014
Actual (reported)October 2014
Actual (reported)April 25, 2017
Actual (reported)Mood Scale - Subscale 'Feeling High'
Participants rated how much they felt having a "high" feeling from smoked marijuana using a visual analog scale 1-100 mm, 1 (Not at all) - 100 (extremely).
two hours before and after marijuana cigarette smoking
Marijuana Rating Form - Like
15 - 120 minutes after marijuana cigarette smoking
Marijuana Rating Form - Strength
15 - 120 minutes after marijuana cigarette smoking
Optional Additional Puffs of MJ Cigarette
150 to 250 minutes after first marijuana cigarette was smoked earlier in the day
Active MJ cigarettes contain 5.30% THC
Active MJ cigarettes contain 5.30% THC
Active MJ cigarettes contain 5.30% THC
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
University of Kentucky, Straus Behavioral Research Bldg., 515 Oldham Ct.
Lexington, Kentucky, 40513, United States
Marijuana Outpatient Lab 1051 Riverside Dr. Unit #120
New York, New York, 10032, United States
Center for Drug and Alcohol Programs, Room 459 North, 67 President St.
Charleston, South Carolina, 29425, United States
Margaret Haney, M.D.
New York State Psychiatric Institute
Robert J Malcolm, M.D.
Medical University of South Carolina
Sharon Walsh, Ph.D.
University of Kentucky
50 participants (actual enrollment reported by the registry).
First Submitted
April 29, 2013
First Posted
May 1, 2013
Study Start
May 2013
Date type not reportedThis date has not been verified as actual or estimated.
A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety
Active MJ cigarettes contain 5.30% THC
Inactive MJ cigarettes contain 0.01% THC
Inactive MJ cigarettes contain 0.01% THC
Inactive MJ cigarettes contain 0.01% THC
Inactive MJ cigarettes contain 0.01% THC
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
October 2014
Actual (reported)Study Completion
October 2014
Actual (reported)Last Updated
December 9, 2019
Results First Posted
April 25, 2017
Record last verified: 2017-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: